Intravenous Ketamine for Cancer Pain: A Single-Center Retrospective Analysis Comparing Fixed-Rate Versus Weight-Based Dosing.

Leslie Siegel, Kyle Quirk, Gary Houchard, Sarah Ehrman, Eric McLaughlin, Omar Hajmousa, Maureen Saphire
{"title":"Intravenous Ketamine for Cancer Pain: A Single-Center Retrospective Analysis Comparing Fixed-Rate Versus Weight-Based Dosing.","authors":"Leslie Siegel, Kyle Quirk, Gary Houchard, Sarah Ehrman, Eric McLaughlin, Omar Hajmousa, Maureen Saphire","doi":"10.1080/15360288.2024.2374297","DOIUrl":null,"url":null,"abstract":"<p><p>Although weak evidence exists to support subanesthetic ketamine for cancer pain treatment, successful use may be hindered in the absence of standardized dosing guidance. We aimed to compare the success rates of intravenous ketamine fixed-rate versus weight-based dosing strategies for cancer pain treatment, and to assess patient characteristics that correlate with treatment success. We conducted a single-center retrospective review including non-critically ill adults with cancer pain who received subanesthetic ketamine for at least 24-h. All patients received fixed-rate ketamine; weight-based doses were retrospectively determined using total body weight. Treatment was considered successful if after reaching the maximum prescribed ketamine dose the patient had a 30% reduction in: baseline pain score, as-needed opioid use, or total morphine equivalent daily dose over a standardized 24-h. Of 105 included patients, 51 (48.6%) successfully responded to ketamine. Responders had lower fixed-rate ketamine doses compared to non-responders (median[IQR] 15 mg/hr[10-15] vs. 15 mg/hr[15-20], <i>p</i> = 0.043), but no difference in retrospectively calculated weight-based doses (0.201 ± 0.09 mg/kg/hr vs. 0.209 ± 0.08 mg/kg/hr, <i>p</i> = 0.59). Responders had higher daily opioid requirements at baseline compared to non-responders (<i>p</i> = 0.04). Though underpowered, our findings suggest that weight-based ketamine dosing may not convey additional benefit over fixed-rate dosing.</p>","PeriodicalId":16645,"journal":{"name":"Journal of Pain & Palliative Care Pharmacotherapy","volume":null,"pages":null},"PeriodicalIF":0.9000,"publicationDate":"2024-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pain & Palliative Care Pharmacotherapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/15360288.2024.2374297","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ANESTHESIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Although weak evidence exists to support subanesthetic ketamine for cancer pain treatment, successful use may be hindered in the absence of standardized dosing guidance. We aimed to compare the success rates of intravenous ketamine fixed-rate versus weight-based dosing strategies for cancer pain treatment, and to assess patient characteristics that correlate with treatment success. We conducted a single-center retrospective review including non-critically ill adults with cancer pain who received subanesthetic ketamine for at least 24-h. All patients received fixed-rate ketamine; weight-based doses were retrospectively determined using total body weight. Treatment was considered successful if after reaching the maximum prescribed ketamine dose the patient had a 30% reduction in: baseline pain score, as-needed opioid use, or total morphine equivalent daily dose over a standardized 24-h. Of 105 included patients, 51 (48.6%) successfully responded to ketamine. Responders had lower fixed-rate ketamine doses compared to non-responders (median[IQR] 15 mg/hr[10-15] vs. 15 mg/hr[15-20], p = 0.043), but no difference in retrospectively calculated weight-based doses (0.201 ± 0.09 mg/kg/hr vs. 0.209 ± 0.08 mg/kg/hr, p = 0.59). Responders had higher daily opioid requirements at baseline compared to non-responders (p = 0.04). Though underpowered, our findings suggest that weight-based ketamine dosing may not convey additional benefit over fixed-rate dosing.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
静脉注射氯胺酮治疗癌症疼痛:固定剂量与按体重给药的单中心回顾性分析比较。
尽管有微弱的证据支持将麻醉下氯胺酮用于癌痛治疗,但由于缺乏标准化的剂量指导,成功使用氯胺酮可能会受到阻碍。我们旨在比较静脉注射氯胺酮固定剂量与基于体重的剂量策略治疗癌症疼痛的成功率,并评估与治疗成功率相关的患者特征。我们进行了一项单中心回顾性研究,研究对象包括接受麻醉下氯胺酮治疗至少 24 小时的非重症成人癌痛患者。所有患者都接受了固定剂量的氯胺酮;根据总重量回顾性地确定了基于体重的剂量。在达到氯胺酮的最大处方剂量后,如果患者的基线疼痛评分、阿片类药物的按需使用量或吗啡当量日总剂量在标准的24小时内减少了30%,则认为治疗成功。在纳入的 105 名患者中,有 51 人(48.6%)对氯胺酮成功产生了反应。与无反应者相比,有反应者的氯胺酮固定剂量较低(中位数[IQR] 15 mg/hr[10-15] vs. 15 mg/hr[15-20], p = 0.043),但回顾性计算的基于体重的剂量没有差异(0.201 ± 0.09 mg/kg/hr vs. 0.209 ± 0.08 mg/kg/hr,p = 0.59)。与无应答者相比,有应答者的基线阿片类药物日需求量更高(p = 0.04)。我们的研究结果表明,基于体重的氯胺酮剂量可能不会比固定剂量带来更多益处。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
1.60
自引率
9.10%
发文量
40
期刊最新文献
Editorial: Reasons for Conflicting Evidence Regarding Use of Platelet-Rich Plasma (PRP). The Effectiveness of Tramadol in Pain Relief in Chronic Diseases: A Review Based on Clinical Trials. Changes in Pain and Mental Health Symptoms Associated with Prescribed Medicinal Cannabis Use: A One-Year Longitudinal Study. Correction. Comparison of Cannabis-Based Medicinal Product Formulations for Fibromyalgia: A Cohort Study.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1